glp-1 therapy help with glp 1 side effects Struggling effects? You're not alone. This Clinician Guide: Managing Common GLP-1 Receptor Agonist Side Schematic overview of the Package:1 Month sfmc-product-catalog

glp-1 therapy help with glp 1 side effects Struggling effects? You're not alone. This Clinician Guide: Managing Common GLP-1 Receptor Agonist Side Schematic overview of the Package:1 Month sfmc-product-catalog

Schematic overview of the benefits and risks associated with GLP-1... | Download Scientific Diagram

our longevity, our metabolic future is still built on the everyday fundamentals: Movement

sfmc-product-catalog

Package:1 Month

Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population